Molecular mechanisms underlying the probiotic effects of Escherichia coli Nissle 1917 involve ZO‐2 and PKCζ redistribution resulting in tight junction and epithelial barrier repair

The probiotic Escherichia coli strain Nissle 1917 (EcN) has been used for decades in human medicine in Central Europe for the treatment and prevention of intestinal disorders and diseases. However, the molecular mechanisms underlying its beneficial effects are only partially understood. To identify molecular responses induced by EcN that might contribute to its probiotic properties polarized T84 cells were investigated employing DNA microarrays, quantitative RT‐PCR, Western blotting, immunofluorescence and specific protein kinase C (PKC) inhibitors. Polarized T84 epithelial cell monolayers were used as a model to monitor barrier disruption by infection with the enteropathogenic E. coli (EPEC) strain E2348/69. Co‐incubation of EPEC with EcN or addition of EcN following EPEC infection abolished barrier disruption and, moreover, restored barrier integrity as monitored by transepithelial resistance. DNA‐microarray analysis of T84 cells incubated with EcN identified 300+ genes exhibiting altered expression. EcN altered the expression, distribution of zonula occludens‐2 (ZO‐2) protein and of distinct PKC isotypes. ZO‐2 expression was enhanced in parallel to its redistribution towards the cell boundaries. This study provides evidence that EcN induces an overriding signalling effect leading to restoration of a disrupted epithelial barrier. This is transmitted via silencing of PKCζ and the redistribution of ZO‐2. We suggest that these properties contribute to the reported efficacy in the treatment of inflammatory bowel diseases and in part rationalize the probiotic nature of EcN.

[1]  F. Shanahan,et al.  The gut flora as a forgotten organ , 2006, EMBO reports.

[2]  B. Finlay,et al.  Human and microbe: united we stand , 2006, Nature Medicine.

[3]  B. Wiedenmann,et al.  Escherichia coli Strain Nissle 1917 Ameliorates Experimental Colitis via Toll-Like Receptor 2- and Toll-Like Receptor 4-Dependent Pathways , 2006, Infection and Immunity.

[4]  R. Black,et al.  Efficacy of probiotics in prevention of acute diarrhoea: a meta-analysis of masked, randomised, placebo-controlled trials. , 2006, The Lancet. Infectious diseases.

[5]  V. DiRita,et al.  Bacterial‐associated cholera toxin and GM1 binding are required for transcytosis of classical biotype Vibrio cholerae through an in vitro M cell model system , 2006, Cellular microbiology.

[6]  V. Lievin-Le Moal,et al.  The Front Line of Enteric Host Defense against Unwelcome Intrusion of Harmful Microorganisms: Mucins, Antimicrobial Peptides, and Microbiota , 2006, Clinical Microbiology Reviews.

[7]  R. Morona,et al.  Designer probiotics for prevention of enteric infections , 2006, Nature Reviews Microbiology.

[8]  T. Tompkins,et al.  Probiotics Reduce Enterohemorrhagic Escherichia coli O157:H7- and Enteropathogenic E. coli O127:H6-Induced Changes in Polarized T84 Epithelial Cell Monolayers by Reducing Bacterial Adhesion and Cytoskeletal Rearrangements , 2005, Infection and Immunity.

[9]  Jennifer M. Smith,et al.  Involvement of protein kinase C in chitosan glutamate-mediated tight junction disruption. , 2005, Biomaterials.

[10]  R. Xavier,et al.  Commensal flora: wolf in sheep's clothing. , 2005, Gastroenterology.

[11]  F. Gunzer,et al.  Intestinal immunity of Escherichia coli NISSLE 1917: a safe carrier for therapeutic molecules. , 2005, FEMS immunology and medical microbiology.

[12]  B. Wiedenmann,et al.  Escherichia coli Nissle 1917 Distinctively Modulates T-Cell Cycling and Expansion via Toll-Like Receptor 2 Signaling , 2005, Infection and Immunity.

[13]  R. Sartor,et al.  Probiotic therapy of intestinal inflammation and infections , 2005, Current opinion in gastroenterology.

[14]  D. Polk,et al.  Commensal bacteria in the gut: learning who our friends are , 2004, Current opinion in gastroenterology.

[15]  M. Stolte,et al.  Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine , 2004, Gut.

[16]  S. Nuding,et al.  NF-κB- and AP-1-Mediated Induction of Human Beta Defensin-2 in Intestinal Epithelial Cells by Escherichia coli Nissle 1917: a Novel Effect of a Probiotic Bacterium , 2004, Infection and Immunity.

[17]  W. Kruis,et al.  Antibiotics and probiotics in inflammatory bowel disease , 2004, Alimentary pharmacology & therapeutics.

[18]  S. Savkovic,et al.  Differing roles of protein kinase C-zeta in disruption of tight junction barrier by enteropathogenic and enterohemorrhagic Escherichia coli. , 2004, Gastroenterology.

[19]  G. Gottschalk,et al.  Analysis of the Genome Structure of the Nonpathogenic Probiotic Escherichia coli Strain Nissle 1917 , 2004, Journal of bacteriology.

[20]  G. Gerken,et al.  Toll-like receptor 2 enhances ZO-1-associated intestinal epithelial barrier integrity via protein kinase C. , 2004, Gastroenterology.

[21]  R. D. Lynch,et al.  The tight junction: a multifunctional complex. , 2004, American journal of physiology. Cell physiology.

[22]  A. Macpherson,et al.  Interactions between commensal intestinal bacteria and the immune system , 2004, Nature Reviews Immunology.

[23]  J. Nataro,et al.  Intestinal epithelial tight junctions as targets for enteric bacteria-derived toxins. , 2004, Advanced drug delivery reviews.

[24]  D. Podolsky,et al.  Functional modulation of enterocytes by gram-positive and gram-negative microorganisms. , 2004, American journal of physiology. Gastrointestinal and liver physiology.

[25]  J. Schölmerich,et al.  Rationale for Probiotic and Antibiotic Treatment Strategies in Inflammatory Bowel Diseases , 2003, Digestive Diseases.

[26]  S. Savkovic,et al.  PKC zeta participates in activation of inflammatory response induced by enteropathogenic E. coli. , 2003, American journal of physiology. Cell physiology.

[27]  K. Barrett,et al.  Live probiotics protect intestinal epithelial cells from the effects of infection with enteroinvasive Escherichia coli (EIEC) , 2003, Gut.

[28]  B. Sartor,et al.  Targeting enteric bacteria in treatment of inflammatory bowel diseases: why, how, and when , 2003, Current opinion in gastroenterology.

[29]  S. Savkovic,et al.  Intestinal epithelial responses to enteric pathogens: effects on the tight junction barrier, ion transport, and inflammation , 2003, Gut.

[30]  M. Sanders Probiotics: Considerations for Human Health , 2003, Nutrition reviews.

[31]  R. Rosenquist,et al.  Minimal residual disease quantification in childhood acute lymphoblastic leukemia by real-time polymerase chain reaction using the SYBR green dye. , 2002, Experimental hematology.

[32]  F. Gunzer,et al.  Gnotobiotic piglets develop thrombotic microangiopathy after oral infection with enterohemorrhagic Escherichia coli. , 2002, American journal of clinical pathology.

[33]  F. Speleman,et al.  Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes , 2002, Genome Biology.

[34]  S. Salminen,et al.  Probiotics: a role in the treatment of intestinal infection and inflammation? , 2002, Gut.

[35]  C. Pothoulakis,et al.  Protein Kinase C Signaling Regulates ZO-1 Translocation and Increased Paracellular Flux of T84 Colonocytes Exposed toClostridium difficile Toxin A* , 2002, The Journal of Biological Chemistry.

[36]  G. Joberty,et al.  Assembly of Epithelial Tight Junctions Is Negatively Regulated by Par6 , 2002, Current Biology.

[37]  C. De Simone,et al.  Probiotic bacteria enhance murine and human intestinal epithelial barrier function. , 2001, Gastroenterology.

[38]  G. Reid,et al.  Can bacterial interference prevent infection? , 2001, Trends in microbiology.

[39]  A. Schulze,et al.  Navigating gene expression using microarrays — a technology review , 2001, Nature Cell Biology.

[40]  O. Farokhzad,et al.  Regulation of epithelial transport and barrier function by distinct protein kinase C isoforms. , 2001, American journal of physiology. Cell physiology.

[41]  T. Ohnishi,et al.  Atypical Protein Kinase C Is Involved in the Evolutionarily Conserved Par Protein Complex and Plays a Critical Role in Establishing Epithelia-Specific Junctional Structures , 2001, The Journal of cell biology.

[42]  M. Kruhøffer,et al.  Identification of gene expression patterns in superficial and invasive human bladder cancer. , 2001, Cancer research.

[43]  S. Dahan,et al.  Saccharomyces boulardii Preserves the Barrier Function and Modulates the Signal Transduction Pathway Induced in Enteropathogenic Escherichia coli-Infected T84 Cells , 2000, Infection and Immunity.

[44]  A. Ávila-Flores,et al.  MAGUK proteins: structure and role in the tight junction. , 2000, Seminars in cell & developmental biology.

[45]  C. V. Van Itallie,et al.  Molecular physiology and pathophysiology of tight junctions I. Tight junction structure and function: lessons from mutant animals and proteins. , 2000, American journal of physiology. Gastrointestinal and liver physiology.

[46]  G. Hecht,et al.  Myosin regulation of NKCC1: effects on cAMP-mediated Cl- secretion in intestinal epithelia. , 1999, American journal of physiology. Cell physiology.

[47]  B. Rembacken,et al.  Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial , 1999, The Lancet.

[48]  D. Philpott,et al.  Signal Transduction Pathways Involved in Enterohemorrhagic Escherichia coli-Induced Alterations in T84 Epithelial Permeability , 1998, Infection and Immunity.

[49]  S. Savkovic,et al.  Enteropathogenic Escherichia coli-induced myosin light chain phosphorylation alters intestinal epithelial permeability. , 1997, Gastroenterology.

[50]  M. Stolte,et al.  Double‐blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis , 1997, Alimentary pharmacology & therapeutics.

[51]  J. Oh,et al.  Activation of host cell protein kinase C by enteropathogenic Escherichia coli , 1997, Infection and immunity.

[52]  S. Savkovic,et al.  Attachment of a noninvasive enteric pathogen, enteropathogenic Escherichia coli, to cultured human intestinal epithelial monolayers induces transmigration of neutrophils , 1996, Infection and immunity.

[53]  B. Kachar,et al.  Identification of Isoforms of G Proteins and PKC that Colocalize with Tight Junctions , 1996, The Journal of Membrane Biology.

[54]  R. O. Stuart,et al.  Regulated assembly of tight junctions by protein kinase C. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[55]  J. Alverdy,et al.  Enteropathogenic Escherichia coli adherence to intestinal epithelial monolayers diminishes barrier function. , 1995, The American journal of physiology.

[56]  M. Möllenbrink,et al.  [Treatment of chronic constipation with physiologic Escherichia coli bacteria. Results of a clinical study of the effectiveness and tolerance of microbiological therapy with the E. coli Nissle 1917 strain (Mutaflor)]. , 1994, Medizinische Klinik.

[57]  D. Podolsky Inflammatory bowel disease (Second of two parts) , 1991 .

[58]  P. Williams,et al.  Protein phosphorylation by protein kinase C in HEp-2 cells infected with enteropathogenic Escherichia coli , 1990, Infection and immunity.

[59]  J. Madara,et al.  Structural analysis of a human intestinal epithelial cell line. , 1987, Gastroenterology.

[60]  A. Nißle Weiteres über Grundlagen und Praxis der Mutaflorbehandlung , 1925 .

[61]  null Nissle Ueber die Grundlagen einer neuen ursächlichen Bekämpfung der pathologischen Darmflora1) , 1916 .

[62]  W. Kruis Review article: antibiotics and probiotics in inflammatory bowel disease. , 2004, Alimentary pharmacology & therapeutics.

[63]  C. Pothoulakis,et al.  Protein Kinase C Signaling Regulates ZO-1 Translocation and Increased Paracellular Flux of T84 Colonocytes Exposed to Clostridium difficile Toxin A* , 2002 .

[64]  U. Sonnenborn,et al.  Effect of preventive administration of a nonpathogenic Escherichia coli strain on the colonization of the intestine with microbial pathogens in newborn infants. , 1997, Biology of the neonate.